# A Dose Escalation and Expansion Study of NB002 in Participants With Advanced or Metastatic Solid Tumors

> **NCT05924906** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Suzhou Neologics Bioscience Co., Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** NB002

## Key facts

- **NCT ID:** NCT05924906
- **Lead sponsor:** Suzhou Neologics Bioscience Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-10
- **Primary completion:** 2026-04
- **Final completion:** 2026-07
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05924906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05924906, "A Dose Escalation and Expansion Study of NB002 in Participants With Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05924906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*